Available Until 5/19/2023

BCIDP Credit from the 2022 Annual MAD-ID Meeting

Description

In collaboration with SIDP, the MAD-ID Annual Antimicrobial Stewardship Meeting is offering 4.75 contact hours toward recertification for Board Certified Infectious Diseases Pharmacists (BCIDP).

Sessions for BCIDP credit are:

  • Keynote: Antimicrobial Stewardship for the Patients We Serve (presented by Matthew B. Goetz, MD)
  • What’s New with COVID?
    • Antimicrobial Stewardship Challenges and Response in the COVID-19 Pandemic (presented by Payal K. Patel, MD, MPH)
  • Implementing Diagnostic Stewardship in 2022
    • These are Exciting Times: Implementing Diagnostic Stewardship into Traditional Antimicrobial Stewardship Programs (presented by Kimberly C. Claeys, PharmD)
    • Rapid Diagnostics: The Clinical Microbiologist Perspective (presented by Kaede Ota Sullivan, MD, MSc, FRCPC, FAAP, D(ABMM))
  • Gram Negative Pathogens
    • Update on Epidemiology and Patient Outcomes (presented by David van Duin, MD, PhD, FIDSA, FAST)
  • Coming Attractions: Innovations in HIV and Fungal Therapy
    • New Developments in HIV, Long-Acting Therapy (presented by Meshell Maxam, PharmD, BCIDP)

Learning Objectives

The target audience for these activities includes board-certified infectious diseases pharmacists (BCIDPs) seeking to update their knowledge and skills related to infectious diseases. Learning objectives for each session are below.

Antimicrobial Stewardship for the Patients We Serve
At the completion of this activity, the participant will be able to:

  • Describe successful interdisciplinary approaches in practice, operations, and research of antimicrobial stewardship.
  • Discuss outcomes measures for stewardship programs: process, antibiotic use and antibiotic resistance.
  • Identify future opportunities and strategies for stewardship programs.

What’s New with COVID? Antimicrobial Stewardship Challenges and Response in the COVID-19 Pandemic
At the completion of this activity, the participant will be able to:

  • Describe the core principles and objectives of diagnostic stewardship.
  • Discuss how antimicrobial stewardship programs and interventions are impacted by the COVID-19 pandemic.
  • Explain a process for staying up to date with rapidly changing treatment recommendations for patients with COVID-19.

Implementing Diagnostic Stewardship in 2022: These are Exciting Times: Implementing Diagnostic Stewardship into Traditional Antimicrobial Stewardship Programs
At the completion of this activity, the participant will be able to:

  • Describe the core principles and objectives of diagnostic stewardship.
  • Discuss the existing evidence to support diagnostic stewardship interventions as part of an antimicrobial stewardship strategy.
  • Identify current controversies and challenges in implementing and evaluating diagnostic stewardship interventions.

Implementing Diagnostic Stewardship in 2022: Rapid Diagnostics: The Clinical Microbiologist Perspective
At the completion of this activity, the participant will be able to:

  • Describe existing and emerging rapid diagnostic tests in infectious diseases.
  • Identify ideal rapid diagnostic testing based on institutional need.
  • Discuss strategies to implement rapid diagnostic testing in critically ill patients to maximize their potential clinical and economic value.

Gram Negative Pathogens: Update on Epidemiology and Patient Outcomes
At the completion of this activity, the participant will be able to:

  • Identify the most challenging MDR gram-negative pathogens.
  • Describe the basis/rationale of the MDR Gram-negative guidance documents.
  • List the recommended treatment for the most challenging MDR Gram-negative pathogens.

Coming Attractions: Innovations in HIV and Fungal Therapy: New Developments in HIV, Long-Acting Therapy
At the completion of this activity, the participant will be able to:

  • Describe the indications for use of long acting ARVs in treatment of HIV infection.
  • Discuss the barriers for use of long acting ARVs and inpatient considerations.
  • Discuss updates to HIV pre-exposure prophylaxis and the role of long-acting ARVs.

Faculty

Kimberly C. Claeys, PharmD
Associate Professor – Infectious Diseases
Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy
Center for Innovation in Diagnosis, University of Maryland School of Medicine
Baltimore, MD

Matthew B. Goetz, MD
Chief, Infectious Diseases, VA Greater Los Angeles Healthcare System
Professor of Clinical Medicine, David Geffen School of Medicine at UCLA
Los Angeles, CA

Meshell Maxam, PharmD, BCIDP
HIV/Infectious Diseases Clinical Pharmacy Specialist, Kaiser Permanente Georgia
Atlanta, GA

Kaede Ota Sullivan, MD, MSc, FRCPC, FAAP, D(ABMM)
Professor and Director of Faculty Affairs
Department of Pathology & Laboratory Medicine, Lewis Katz School of Medicine at Temple University
Associate Director of Clinical Microbiology & Immunology, Temple University Health System
Philadelphia, PA

Payal K. Patel, MD, MPH
Assistant Professor, Division of Infectious Diseases, University of Michigan Health System
Ann Arbor, MI

David van Duin, MD, PhD, FIDSA, FAST
Professor of Medicine
Director, Immunocompromised Host Infectious Diseases Program, Division of Infectious Diseases, University of North Carolina
Chapel Hill, NC

Accreditation

Release Date: May 19, 2022
BCIDP Expiration Date: May 19, 2023

Pharmacists

ACPE LogoThis activity is jointly provided by ProCE, LLC and the Society of Infectious Diseases Pharmacists. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Numbers 0221-9999-22-188-H01-P, 0221-9999-22-189-H01-P, 0221-9999-22-190-H01-P, 0221-9999-22-191-H01-P, 0221-9999-22-192-H01-P and 0221-9999-22-193-H01-P have been assigned to these home-study knowledge-based activities. The first activity is approved for 1.0 contact hour (0.1 CEU) and the remaining activities are each approved for 0.75 contact hour (0.075 CEU) in states that recognize ACPE providers. Statements of completion will be issued online at www.ProCE.com upon completion of the evaluation and post-test with a score of 70% or higher. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

BCIDP

The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of a post-test and online evaluation. The post-test must be successfully completed in only one attempt. No partial credit will be given. BCIDP accreditation begins 5/19/2022 for each activity and is available for one year from this date.

Recertification Criteria for Infectious Diseases Pharmacy: BCIDP recertifying via continuing education are required to earn 100 hours of continuing education credit provided by the joint program offered by the Society of Infectious Diseases Pharmacists (SIDP), American College of Clinical Pharmacy (ACCP) and/or the American Society of Health-System Pharmacists (ASHP). Infectious Diseases Pharmacy Specialty Recertification Courses offered by any of the approved providers may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle. Candidates should note that there are expiration dates associated with earning BPS recertification credit. BPS will only award recertification credit for modules based on the completion and submission date of the post-test assessment. For example, a module completed and submitted on October 20 of a particular year will only be credited for that year, even if the due date of the post-test is in January of the following year. View all recertification criteria on the BPS website at https://www.bpsweb.org/recertification/recertification-by-continuing-education

Disclosure

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Matthew B. Goetz has no relevant conflicts to disclose. Kaede Ota Sullivan has no relevant conflicts to disclose. Meshell Maxam has no relevant conflicts to disclose. Payal K. Patel has served as a consultant/advisor/speaker for Qiagen. Kimberly C. Claeys has served as a consultant/advisor/speaker for BioFire Diagnostics and La Jolla Pharmaceuticals and as a researcher for Merck. David van Duin has served as a consultant/advisor/speaker for Shionogi, Merck, Pfizer, Roche, Opex, Entasis, Union, and Utility.

Funding

No external support has been received for this activity.

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.